Funding

Canadian Institutes for Health Research Foundation grant

July 2019 - June 2026, $5.78 million

US Department of Defense Congressionally Directed Multiple Sclerosis Research Program

Defining and Overcoming a Novel Extracellular Matrix Inhibitor of Remyelination in MS: Fibulin-2, US$200,000 per annum, 2022-2025

Multiple Sclerosis Canada team program

Canadian Progression Cohort in MS (CanProCo), 2019-2024. Co-investigator (overall lead: Jiwon Oh), my portion is about CAD$80,000 per annum. 

Phase 1.5 extension, 2025-2028, my portion is about CAD$50,000 per annum.

Multiple Sclerosis Canada discovery grant

PI: Yong, Co-PI: CC Ling. Overcoming neurofibrosis in MS by targeting PDGFRb+ fibroblasts, $300,000, 2024-2027

Canadian Foundation for Innovation

Micro and mesoscale imaging of neurodegeneration and repair in MS, Co-investigator (overall lead: Jeff Dunn and Peter Stys), $4,497,691 for equipment

VPR Catalyst grant

Characterizing the extracellular matrix landscape in chronic active multiple sclerosis lesions: a springboard to understanding disability progression, $12,500 (written with postdoc Rianne Gorter)

International Progressive MS Alliance

Development grant of Experimental Medicine Trial Award, on: Positioning salbutamol, alone and in combination with ibudilast, for progressive MS, 100,000 euros for 1.5 years, from February 2025

Alberta Cancer Foundation

NiacinCNS2020: A Phase I-II Study of Niacin In Patients with Newly Diagnosed Glioblastoma Receiving Concurrent Radiotherapy and Temozolomide Followed by Monthly Temozolomide, $300,000, July 1 2025-June 30 2028 (co-PIs: Gloria Roldan Urgoiti and Wee Yong)

Canadian Institutes of Health Research

Identifying and countering undesirable extracellular matrix components in lesions of multiple sclerosis, PI: Yong, Co-PI: CC Ling, $1,132,000 over 5 years from (deferring start by 1 year), July 1 2026 - June 30 2031